The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
“Be courageous: Your work will be recognized, and everything is about [the] work in the end.”
Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.
A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
A leading expert in the field of esophageal cancers discussed his upcoming research on cabozantinib combined with pembrolizumab to treat gastroesophageal adenocarcinoma at the 2021 ASCO Gastrointestinal Cancers Symposium.
Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape.
A systematic review of reported clinical cases and treatment strategies was performed to better understand the prognostic factors and to develop the best possible treatment option for a 16-year-old patient diagnosed with a malignant triton tumor in the lower extremity with distant metastases in the lungs.
Suneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Jason M. Hafron, MD, CMO, and Oliver Sartor, MD, share their approach for the optimal management of mCRPC through genetic testing.
This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.
Brett L. Ecker, MD, discusses the importance of multidisciplinary collaboration in improving patient outcomes in neuroendocrine tumors.
Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.
A prospective trial may help affirm ctDNA as a non-invasive option of predicting responses to radiotherapy among those with gynecologic cancers.
The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.
Determining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Data from the phase 3 OPERA trial support contact X-ray brachytherapy boost as a treatment option for preserving organs in smaller rectal adenocarcinoma tumors.
For patients with HMA–naive chronic myelomonocytic leukemia, an IO-202 combo demonstrated durable responses, a phase 1b study found.
Patient-reported outcomes from the EV-302 trial found consistent efficacy and safety outcomes for patients with urothelial carcinoma.
Panelists discuss how community centers can effectively implement bispecific antibody therapy for patients with relapsed/refractory multiple myeloma, addressing challenges such as staff training, patient monitoring, and managing potential adverse events in a non-academic setting.